Lundbeck
Four Parkway North
Suite 200
Deerfield
Illinois
60015
United States
Tel: 800-455-1141
Fax: 847-282-1001
Website: http://www.lundbeckinc.com/
Email: contact@lundbeck.com
About Lundbeck
Lundbeck Inc. - Making a Difference One Patient at a TimeHeadquartered in Deerfield, Illinois, with a portfolio of 17 specialty therapies and a pipeline of promising central nervous system (CNS) drugs, Lundbeck Inc. is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available.
As a wholly-owned subsidiary of H. Lundbeck A/S of Denmark, Lundbeck Inc. has a unique ownership structure. The company is 70 percent owned by the Lundbeck Foundation, which contributes millions annually to scientific research. In 2009, the Foundation granted more than $58 million to support research in biomedical and natural sciences.
Lundbeck Inc. offers the chance to make a difference while working in a unique and innovative environment. We are united by our passion and responsibility for helping the people with unmet medical needs. In addition to our extensive CNS pipeline that addresses a range of disorders from Alzheimer’s disease to Parkinson’s disease and depression, Lundbeck focuses on rare diseases with five orphan-designated therapies on the market and one more in late-stage development.
Our team of 350 pharmaceutical professionals, including an experienced team of clinical, regulatory and commercial experts, has a proven track record of working effectively with the U.S. Food and Drug Administration, developing and marketing high-need drugs that improve patients’ lives, and quickly and cost effectively bringing new products to market. Our operational excellence, diverse commercial portfolio and compelling development pipeline puts us in an excellent position for continued innovation and growth that will benefit patients for years to come.
At Lundbeck you can make a difference one patient at a time. If you wish to join a team where the challenges are great, the mission is meaningful and you can directly see the results of your hard work, Lundbeck may be the place for you.
176 articles with Lundbeck
-
Lundbeck Tops Corporate Reputation Rankings for Fourth Consecutive Year
5/31/2019
Annual survey finds Lundbeck US is first among leading pharmaceutical companies in the eyes of patient groups.
-
The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.
-
Numerate and Lundbeck Partner to Apply AI Drug Discovery to Unlock Challenges of Neuroscience Research
1/7/2019
Collaboration sets out to identify potential treatment candidates for disorders of the central nervous system including depression, psychosis, seizure and neurodegenerative disorders.
-
Survey Findings Highlight the Burden of Neurogenic Orthostatic Hypotension (nOH) on Patients and Care Partners
9/24/2018
Symptoms of nOH may affect approximately one in five people with Parkinson’s Disease
-
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the firs...
-
Catalyst Pharmaceuticals Expands Commercial Leadership Team
8/6/2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.
-
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
5/23/2018
Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.
-
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
-
Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.
-
Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LGS)
12/4/2017
Lundbeck today presented data at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. that demonstrates that the Refractory Epilepsy Screening Tool for LGS (REST-LGS) may help healthcare professionals identify patients who may benefit from further clinical evaluation for Lennox-Gastaut syndrome (LGS).
-
Otsuka Pharma And Lundbeck Announce Initiation Of Two Phase III Trials Of Brexpiprazole In Patients With Bipolar I Disorder
10/12/2017
-
Otsuka Pharmaceutical Development & Commercialization, Inc. And Lundbeck To Showcase Safety And Efficacy Data In Treatments For Challenging Mental Health Conditions
9/13/2017
-
Lundbeck Reports 13% Revenue Growth And A Doubling Of EBIT In First Half Of 2017
8/9/2017
-
Lundbeck Collaborates On Large First-Of-Its Kind Study Of Links Between Genetics And Psychiatric Disorders
8/2/2017
-
Otsuka Pharma And Lundbeck Announce Results Of Brexpiprazole On Symptoms Of Agitation Related To Alzheimer’s-Type Dementia
5/2/2017
-
Mixed Data For Alzheimer’s-Type Dementia Drug Leave Lundbeck, Otsuka Pharma Investors Unsettled
5/2/2017
-
Health Canada Approves Otsuka Pharma And Lundbeck's REXULTI (Brexpiprazole) As A Treatment For Schizophrenia In Adults
2/20/2017
-
Circuit Therapeutics Announces Research Collaboration With Lundbeck Inc.
12/19/2016
-
Citizens United For Research In Epilepsy (CURE) And Lundbeck Inc. Announce National Launch Of Education Enrichment Fund
12/2/2016
-
Citizens United For Research In Epilepsy (CURE) And Lundbeck Inc. Announce National Launch Of Education Enrichment Fund
12/2/2016